Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
- Author
- ROUSSELOT, Philippe1 2 ; HUGUET, Francoise3 ; GARDEMBAS, Martine9 ; MAHON, Francois-Xavier10 ; REA, Delphine1 ; LEGROS, Laurence4 ; CAYUELA, Jean Michel5 ; MAAREK, Odile5 ; BLANCHET, Odile6 ; MARIT, Gerald7 ; GLUCKMAN, Eliane1 ; REIFFERS, Josy8
[1] Fédération d'hématologie et Centre d'Investigation Clinique, Hôpital Saint-Louis, Paris, France
[2] Service d'Hématologie et d'Oncologie, Hôpital Mignot, Versailles, France
[3] Service d'Hématologie, Hôpital de Purpan, Toulouse, France
[4] Service d'hématologie, Hôpital Larchet, Nice, France
[5] Laboratoire Central d'Hématologie, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U) 728, Hôpital Saint-Louis, Paris, France
[6] Laboratoire d'hématologie, Centre Hospitalo-Universitaire (CHU) d'Angers, France
[7] Service des Maladies du Sang, CHU du Haut Lévèque, Pessac, France
[8] Institut Bergonié, Bordeaux, France
[9] Service d'Hématologie, CHU d'Angers, France
[10] Laboratoire Hématopoïèse normale et leucemique, Université Victor Ségalen Bordeaux 2, INSERM E217, France
Intergroupe Francais des Leucémies Myéloïdes Chronique (FIΦLMC), France - Source
Blood. 2007, Vol 109, Num 1, pp 58-60, 3 p ; ref : 9 ref
- ISSN
- 0006-4971
- Scientific domain
- Medical oncology; Hematology
- Publisher
- The Americain Society of Hematology, Washington, DC
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Homme Hématologie Imatinib Rémission Inhibiteur de la tyrosine kinase Leucémie myéloïde chronique STI 571 Enzyme Hémopathie maligne Inhibiteur enzyme Protein-tyrosine kinase Transferases
- Keyword (en)
- Antineoplastic agent Human Hematology Imatinib Remission Chronic myelocytic leukemia Enzyme Malignant hemopathy Enzyme inhibitor Protein-tyrosine kinase Transferases
- Keyword (es)
- Anticanceroso Hombre Hematología Imatinib Remisión Leucemia mieloidea Enzima Hemopatía maligna Inhibidor enzima Protein-tyrosine kinase Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18409000
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1182/blood-2006-03-011239 
https://dx.doi.org/10.1182/blood-2006-03-011239
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2006-03-011239\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"58\";s:8:\"\u0000*\u0000epage\";s:2:\"60\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"ROUSSELOT\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Philippe\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:17:\"HUGUET, Francoise\";i:1;s:18:\"GARDEMBAS, Martine\";i:2;s:22:\"MAHON, Francois-Xavier\";i:3;s:13:\"REA, Delphine\";i:4;s:16:\"LEGROS, Laurence\";i:5;s:20:\"CAYUELA, Jean Michel\";i:6;s:13:\"MAAREK, Odile\";i:7;s:15:\"BLANCHET, Odile\";i:8;s:13:\"MARIT, Gerald\";i:9;s:16:\"GLUCKMAN, Eliane\";i:10;s:14:\"REIFFERS, Josy\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"3\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2006-03-011239\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"58\";s:8:\"\u0000*\u0000epage\";s:2:\"60\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"ROUSSELOT\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Philippe\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:17:\"HUGUET, Francoise\";i:1;s:18:\"GARDEMBAS, Martine\";i:2;s:22:\"MAHON, Francois-Xavier\";i:3;s:13:\"REA, Delphine\";i:4;s:16:\"LEGROS, Laurence\";i:5;s:20:\"CAYUELA, Jean Michel\";i:6;s:13:\"MAAREK, Odile\";i:7;s:15:\"BLANCHET, Odile\";i:8;s:13:\"MARIT, Gerald\";i:9;s:16:\"GLUCKMAN, Eliane\";i:10;s:14:\"REIFFERS, Josy\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"3\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2006-03-011239\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2006-03-011239\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"58\";s:8:\"\u0000*\u0000epage\";s:2:\"60\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"ROUSSELOT\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Philippe\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:17:\"HUGUET, Francoise\";i:1;s:18:\"GARDEMBAS, Martine\";i:2;s:22:\"MAHON, Francois-Xavier\";i:3;s:13:\"REA, Delphine\";i:4;s:16:\"LEGROS, Laurence\";i:5;s:20:\"CAYUELA, Jean Michel\";i:6;s:13:\"MAAREK, Odile\";i:7;s:15:\"BLANCHET, Odile\";i:8;s:13:\"MARIT, Gerald\";i:9;s:16:\"GLUCKMAN, Eliane\";i:10;s:14:\"REIFFERS, Josy\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"3\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2006-03-011239\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"58\";s:8:\"\u0000*\u0000epage\";s:2:\"60\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"ROUSSELOT\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Philippe\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:17:\"HUGUET, Francoise\";i:1;s:18:\"GARDEMBAS, Martine\";i:2;s:22:\"MAHON, Francois-Xavier\";i:3;s:13:\"REA, Delphine\";i:4;s:16:\"LEGROS, Laurence\";i:5;s:20:\"CAYUELA, Jean Michel\";i:6;s:13:\"MAAREK, Odile\";i:7;s:15:\"BLANCHET, Odile\";i:8;s:13:\"MARIT, Gerald\";i:9;s:16:\"GLUCKMAN, Eliane\";i:10;s:14:\"REIFFERS, Josy\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"3\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
